Skip to content

Treatment of hallucinated "voices" with repetitive transcranial magnetic stimulation: Mechanism and efficacy.

Mechanism and efficacy of low frequency rTMS treatment in schizophrenic patients with auditory hallucinations: An fMRI study.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON28865
Enrollment
48
Registered
2009-05-14
Start date
2006-09-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia Auditory-verbal hallucinations

Interventions

1. 1 Hz repetitive transcranial magnetic stimulation
2. 12 sessions of 20 minutes, over 6 consecutive working days
3. Stimulation intensity set at 90% of resting motor threshold.

Sponsors

University of Groningen & University Medical Center Groningen, Department of Neuroscience
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Inpatients as well as outpatients can participate. All patients should meet the diagnostic criteria for schizophrenia or schizoaffective disorder, and should report fairly frequent auditory hallucinations (at least daily). This inclusion information will be based on the patient’s medical file and a structured psychiatric interview (Schedules for clinical Assessments in Neuropsychiatry, SCAN) conducted at intake). Patients should also meet the criteria for medication resistance, defined as persistent auditory hallucinations occurring in face of at least two adequate trials of antipsychotic medication. Patients stay on their regular medication for the complete duration of the study.

Exclusion criteria

Exclusion criteria: Exclusion criteria include rTMS contraindications (e.g. a personal or family history of epileptic seizures, past neurosurgical procedures, intracerebral or pacemaker implants, inner ear prosthesis or other metal prosthetics/implants), neurological disorders, history of significant head trauma, severe behavioral disorders, and current substance abuse. For safety reasons we will also exclude female participants who may be pregnant. Subjects must show decision competence. Patients admitted under BOPZ regulation are not allowed to participate. Furthermore, the ability to give informed consent will be assessed by the patient’s psychiatrist or clinical psychologist. Only subjects who are fully capable of making their own decision regarding participation in the research will be included. Patients with an active psychosis cannot participate due to a lack of concentration and understanding necessary for completion of the procedure.

Design outcomes

Primary

MeasureTime frame
Auditory Hallucination Rating Scale (AHRS).

Secondary

MeasureTime frame
1. Positive and Negative Affect Scale (PANAS); 2. Beliefs about Voices Questionnaire (BAVQ); 3. Positive and Negative Syndrome Scale (PANSS); 4. Hallucination item P3.

Contacts

Public ContactA. Vercammen
a.vercammen@med.umcg.nl+31 (0)50 363 8999

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)